Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Understand the Outcomes of Inflammatory Bowel Disease (IBD) Patients Treated With Biologics in Taiwan - A Decentralized Vedolizumab and Biologic Agents Core Assessments in IBD Collaboration

NCT05596422 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT05596422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05596422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Understand the Outcomes of Inflammatory Bowel Disease (IBD) Patients Treated With Biologics in Taiwan - A Decentralized Vedolizumab and Biologic Agents Core Assessments in IBD Collaboration
Lead sponsor
Takeda
Phase
Observational
Overall status
Completed
Start date
May 27, 2021
Completion date
December 8, 2022
Enrollment
423 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease, inflammatory bowel disease (ibd), ulcerative colitis